Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients

1 Jun 2017

Abstract excerpt

The approval, in 2015, of the first poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib, Lynparza) for platinum-sensitive relapsed high-grade ovarian cancer with either germline or somatic BRCA1/2 deleterious mutations is changing the way that BRCA1/2 testing services are offered to patients with ovarian cancer. Ovarian cancer patients are now being referred for BRCA1/2 genetic testing for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29248130
DOI: 10.1053/j.seminoncol.2017.08.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer PatientsPMID 29248130Read ↗

An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice.Semantic proximity Read ↗

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic PredispositionSemantic proximity Read ↗

Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor TherapySemantic proximity Read ↗

Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH).Semantic proximity Read ↗

BRCA mutations: Implications of genetic testing in ovarian cancer.Semantic proximity Read ↗

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.Semantic proximity Read ↗

BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar populationSemantic proximity Read ↗

Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysisSemantic proximity Read ↗

Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.Semantic proximity Read ↗

Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancerSemantic proximity Read ↗

NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.Semantic proximity Read ↗

Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease PreventionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.